Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar
Also Receives UK Approval For Lutio Generic Version Of Spiriva
Executive Summary
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
You may also be interested in...
Yoshindo Bags Biocon Biosimilars Rights In First Post-Lupin Deal
Yoshindo has gained exclusive Japanese commercialization rights to Biocon Biologic’s ustekinumab and denosumab candidates in a new deal. It comes a month after Yoshindo saw former partner Lupin take their own denosumab project elsewhere.
No Cash Boost For Novartis From Sandoz Spin-Off
After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.
Alvotech Makes It Four With Denosumab Trial
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.